Search hospitals > South Carolina > Greer

Gibbs Cancer Center-Pelham

Claim this profile
Greer, South Carolina 29651
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
167 reported clinical trials
13 medical researchers
Photo of Gibbs Cancer Center-Pelham in GreerPhoto of Gibbs Cancer Center-Pelham in Greer

Summary

Gibbs Cancer Center-Pelham is a medical facility located in Greer, South Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Gibbs Cancer Center-Pelham is involved with conducting 167 clinical trials across 332 conditions. There are 13 research doctors associated with this hospital, such as Michael Humeniuk, Amarinthia (Amy) Curtis, Vikas Dembla, and Jeremy M. Kilburn.

Area of expertise

1Cancer
Global Leader
Gibbs Cancer Center-Pelham has run 80 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Gibbs Cancer Center-Pelham has run 40 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Gibbs Cancer Center-Pelham

Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Bladder Cancer
Tumors
Melanoma
Squamous Cell Carcinoma
Prostate Cancer
Image of trial facility.

Support Program

for Breast Cancer

This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Gibbs Cancer Center-Pelham?
Gibbs Cancer Center-Pelham is a medical facility located in Greer, South Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Gibbs Cancer Center-Pelham is involved with conducting 167 clinical trials across 332 conditions. There are 13 research doctors associated with this hospital, such as Michael Humeniuk, Amarinthia (Amy) Curtis, Vikas Dembla, and Jeremy M. Kilburn.